Analysis of multi-drug resistant pulmonary tuberculosis curative effect and drug safety risk in long-term therapy of amikacin

Abstract

Objective To analysis multi-drug resistant pulmonary tuberculosis curative effect and safety in long-term therapy of amikacin. Methods 86 cases of patients with multi-drug resistant pulmonary tuberculosis fitting for the demands from January 2010 to March 2014 were selected as the research objects, according to visiting sequence number.They were divided into the control group and the observation group (each 43 cases). All patients underwent pyrazinamide (PZA) + ethambutol hydrochloride (EMB) + sodium aminosalicylate (PAS) + levofloxacin (LVFX) + protionamide (PTH) chemotherapy, amikacin was added to the control group for 6 months, the observation group was treated with long-term therapy of amikacin for 12 months, totally 24 months, lesions absorption situation in the two groups at different time segment in the treatment were observed, the sputum negative conversion rate was recorded, blood routine, hepatic and renal function were monitored, drug safety was observed. Results ①There was no significant difference in the sputum negative conversion rate, lesions absorption rate, effective rate of treatment between the two groups in the treatment of 6 months (P>0.05), in the treatment of 12 months, 18 months, the sputum negative conversion rate of observation group were 68.29%, 73.17%, which were significantly higher than the control group (P 0.05). Conclusions Long-term therapy of amikacin can improve the sputum negative conversion rate of patients with multi-drug resistant pulmonary tuberculosis, promote lesions absorption, and improve the curative effect, although the prevalence of nephrotoxicity and ototoxicity of patients who received long-term therapy are high, most are reversible. Key words: Amikacin; Pulmonary tuberculosis, multi-drug resistant; Long-term therapy; Safety